Statement of SKAN Group AG on an investigation by the Office of the Attorney General of Switzerland
May 25, 2023 at 01:03 am EDT
Share
SKAN AG / Key word(s): Miscellaneous
Statement of SKAN Group AG on an investigation by the Office of the Attorney General of Switzerland
25-May-2023 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.
Ad hoc announcement pursuant to Art. 53 LR
Statement of SKAN Group AG on an investigation by the Office of the Attorney General of Switzerland
Allschwil, 25 May 2023 – SKAN Group AG confirms that the Office of the Attorney General of Switzerland has initiated an investigation. The investigation relates to transactions with shares of BV Holding AG from the time before the IPO.
As soon as further findings result from the investigation, SKAN Group will inform again.
Publication of the half-year results 2023
Publication annual results 2023
Annual General Meeting 2024
SKAN – together always one step ahead
SKAN is a pioneer in the field of aseptic and aseptic-toxic manufacturing processes for the (bio)pharmaceutical industry. The company is the market and technology leader for high-quality, process-critical isolator systems for filling drugs according to strict sterility standards. In addition, the company offers its customers process support, services and consumables. Innovative solutions and an efficient life-cycle support organization make SKAN an important partner for the pharmaceutical and biotech industry, CMOs (Contract Manufacturing Organizations) and research laboratories worldwide. Founded in 1968, SKAN today employs over 1170 people. More than half of them work at the Allschwil headquarters in the Life Sciences Hub of the Basel region. The other employees are located among the subsidiaries in Switzerland, Germany, Belgium, Japan and the USA.
SKAN Group AG, former BV Holding AG, is a Switzerland-based holding company of an equity investment group, engaged in the participation in enterprises in Switzerland. It concentrates on companies from the industry, micro and medical technology, processing and material technology, information technology and related services. Target enterprises are those being in special situations, such as management buy-out and buy-in, changes in shareholdersâ structure, succession financing, as well as coming through growth or expansion phase. The Company acts as an entrepreneurial partner in the long term. Operational activities are delegated to the independent advisor BV Partners AG. BV Holding AG and BV Partners AG form the BVgroup. As of December 31, 2011, its investment portfolio included nine companies: Covalys BioSciences AG, E2E Technologies Ltd., Lonstroff Holding AG, Piexon AG, POLYDATA AG, SKAN Holding AG, Sphinx Werkzeuge AG, Ypsomed Holding AG and Ziemer Group AG.